As the only industry-led forum providing biopharma with the insights necessary to make strategic and scientific decisions on their fibrosis pipeline, the 6th
BenevolentAI has discovered a second novel target for idiopathic pulmonary fibrosis (IPF), which AstraZeneca has added to its drug development portfolio, resulting in a milestone payment to the Lon
Privately-held biotech Galecto has raised $64m with an equity funding round to further research into treatments for drugs including a potential inhaled idiopathic pulmonary fibrosis (IPF) m
Boehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for idiopathic pulmonary fibrosis (IPF).
Bristol-Myers Squibb has expanded a long-running alliance with Evotec once again, paying another $50 million upfront to deepen their collaboration on drugs to treat neurod